Geoffrey B. Johnson, MD, PhD, presented “Radioligand Therapy in Prostate Cancer” during the 33rd International Prostate Cancer Update on January 24, 2023, in Vail, Colorado.
How to cite: Johnson, Geoffrey B. “Radioligand Therapy in Prostate Cancer.” January 24, 2023. Accessed Nov 2024. https://grandroundsinurology.com/radioligand-therapy-in-prostate-cancer/
Radioligand Therapy in Prostate Cancer – Summary
Geoffrey B. Johnson, MD, PhD, Chair of the Division of Nuclear Medicine at the Mayo Clinic in Rochester, MN, discusses radioligand therapy in prostate cancer. Dr. Johnson briefly reviews the specific activity of this therapy, with a focus on Lutetium-177-PSMA-617.
Dr. Johnson highlights the benefits and tolerable side-effects of Lutetium-177-PSMA-617, and mentions the therapy is approved for patients with metastatic castrate-resistant prostate cancer who have been previously treated with androgen receptor pathway inhibition and taxane-based therapy.
The presentation further explores the process of patient selection for PSMA imaging, with the requirement of at least one lesion that shows higher PSMA expression than the liver. Dr. Johnson showcases post-therapy imaging examples, and discusses the potential of advanced scanning techniques, such as CZT-based scanners, which offer higher sensitivity and faster scans for accurate tracking of therapy response.
Dr. Johnson emphasizes the promising future of radionuclide therapy. He mentions the potential combinations of PSMA therapy with hormonal therapy, chemotherapy, immunotherapy, and external radiation. Additionally, he mentions ongoing trials exploring the use of alpha and beta emitters and the incorporation of different targets.
About The 33rd Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 33rd iteration of the meeting occurred January 22-25, 2023 in Vail, Colorado. To view more educational presentations from IPCU 33, visit our collection page.
ABOUT THE AUTHOR
Dr. Geoffrey Johnson is a thoracic radiologist and nuclear medicine physician at the Mayo Clinic in Rochester, MN and is chair of the nuclear medicine division. He received his undergraduate degree in chemical engineering at MIT, his medical degree from the Mayo Clinic School of Medicine, and his Ph.D. in Immunology from Mayo Graduate School. He specializes in nuclear cardiology, nuclear medicine, thoracic imaging, and nuclear radiology and is experienced in nuclear therapy, amyloidosis, positron emission tomography (PET/CT and PET/MR), and lung neoplasms. He has a joint appointment in immunology.
Dr. Johnson’s research interests include PET and SPECT imaging of malignancy, infectious and inflammatory diseases, cardiac and systemic amyloidosis and radionuclide therapy. He has served as principal investigator (PI) and co-principal investigator on radionuclide therapy trials and was the PI on the Mayo Clinic’s early access protocol for 68Ga-PSMA-11 PET imaging.
